TY - JOUR
T1 - Pharmacotherapy for obsessive-compulsive disorder
AU - Hollander, E.
AU - Kaplan, A.
AU - Allen, A.
AU - Cartwright, C.
PY - 2000
Y1 - 2000
N2 - SSRIs and the tricyclic antidepressant clomipramine are the first-line therapies for patients with OCD, with the side-effect profile of SSRIs being more favorable than that of clomipramine. As many as 40% to 60% of patients with OCD may not respond to adequate trials of SRIs. Not all patients tolerate SSRIs, and delays in full therapeutic responses often occur. Thus, other pharmacologic approaches to treating patients with OCD have been investigated. Augmentation and monotherapy have been explored with serotonergic enhancers, dopamine and 5-HT antagonists, enhancers of second-messenger systems, and GABAergic agents with varying efficacy.
AB - SSRIs and the tricyclic antidepressant clomipramine are the first-line therapies for patients with OCD, with the side-effect profile of SSRIs being more favorable than that of clomipramine. As many as 40% to 60% of patients with OCD may not respond to adequate trials of SRIs. Not all patients tolerate SSRIs, and delays in full therapeutic responses often occur. Thus, other pharmacologic approaches to treating patients with OCD have been investigated. Augmentation and monotherapy have been explored with serotonergic enhancers, dopamine and 5-HT antagonists, enhancers of second-messenger systems, and GABAergic agents with varying efficacy.
UR - http://www.scopus.com/inward/record.url?scp=0033856171&partnerID=8YFLogxK
U2 - 10.1016/S0193-953X(05)70186-6
DO - 10.1016/S0193-953X(05)70186-6
M3 - Article
C2 - 10986733
AN - SCOPUS:0033856171
SN - 0193-953X
VL - 23
SP - 643
EP - 656
JO - Psychiatric Clinics of North America
JF - Psychiatric Clinics of North America
IS - 3
ER -